Authors : Talaat Dabaghi Ghaleh, Fatemeh Lalooha, Faride Movahed, Simindokht Moradi and Omid Mashrabi
Abstract: Postpartum hemorrhage ranks among the leading causes of maternal morbidity and mortality, both in developed and developing countries. Intravenous Oxytocin is using now to reduce of postpartum hemorrhage. With this trial, researchers sought to determine the effectiveness of oral Misoprostol as an Uterotonic drug in comparison with intravenous Oxytocin in patients with a low risk of postpartum hemorrhage undergoing delivery. To compare the effect of 400 μg of oral Misoprostol with 10 IU of intravenous Oxytocin in preventing postpartum hemorrhage. In a randomized controlled trial conducted in Kosar hospital, 300 pregnant women with inclusion criteria received either 400 μg of oral Misoprostol or 10 IU of intravenous Oxytocin after delivery of the anterior shoulder or within 1 min of delivery. Hemoglobin and hematocrit of maternal was checked during admission and 24 h after delivery and compared together. There was no difference between two groups in hematocrit drop in 3.33±3.44 and 2.81±1.26% of the participants in the Oxytocin and Misoprostol group (p = 0.325). The rate of use of additional oxytocin was higher in the Oxytocin group (34.8 vs. 20.5%, p = 0.013). Shivering was higher in misoprostol group (12.3 vs. 2.9%, p = 0.005). Fever occurred only in 2 cases of Misoprostol group (p = 0.236). The routine use of 400 μg of oral misoprostol was no less effective than 10 IU of intravenous oxytocin in reducing blood loss after delivery as assessed by change in postpartum hematocrit and hemoglobin.
Talaat Dabaghi Ghaleh, Fatemeh Lalooha, Faride Movahed, Simindokht Moradi and Omid Mashrabi, 2011. Comparison of Oxytocin and Misoprostol in Reduction of Postpartum Hemorrhage. Research Journal of Biological Sciences, 6: 652-655.